Sterile Drug Product Facility receives planning permission at Cruiserath Campus Site, creating 350 jobs by 2026
Bristol Myers Squibb today formally announces the investment $400 million at its Dublin 15 Cruiserath Campus towards the build and design of a Sterile Drug Product (SDP) facility, which will support the manufacturing and supply of existing medicines as well as serve as a launch excellence facility for pipeline assets. This will be Bristol Myers Squibb’s first European sterile drug product facility for biologics manufacturing. This will be Bristol Myers Squibb’s first European Biologics sterile drug product facility.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
